重组蜂毒多肽LSSDR412抑制宫颈癌恶性行为实验研究
该研究通过化学合成获得蜂毒多肽LSSDR412,在Hela和Caski细胞及裸鼠移植瘤和肺转移模型中检测其对宫颈癌恶性生物学行为的影响及机制。LSSDR412可抑制细胞增殖、迁移、侵袭和EMT,并通过CLDN4介导的Wnt/β-catenin通路发挥抗肿瘤作用,体内实验显示肿瘤重量、Ki-67阳性率和肺转移灶占比显著降低。
要点
- LSSDR412呈浓度依赖性地降低Hela和Caski细胞存活率、克隆数及侵袭迁移能力。
- LSSDR412通过抑制CLDN4介导的Wnt/β-catenin信号通路和EMT发挥抗宫颈癌作用。
- 裸鼠体内实验显示LSSDR412降低瘤重、Ki-67阳性率及肺转移灶占比,肝肾无明显病理改变。
核心结论
- 多肽LSSDR412对宫颈癌细胞增殖、迁移和侵袭均有显著抑制作用且无明显药物毒副作用。
- 其抗肿瘤活性主要通过抑制CLDN4介导的Wnt/β-catenin信号通路发挥作用。
研究设计与样本
- 研究为体外细胞实验与裸鼠体内移植瘤及肺转移模型的实验研究。
- 体外使用Hela和Caski细胞系,以不同浓度LSSDR412处理,检测存活、增殖、迁移和侵袭。
- 体内构建宫颈癌荷瘤裸鼠皮下移植瘤模型和肺转移模型,腹腔注射LSSDR412后检测瘤体重量、Ki-67表达和肺转移灶。
主要发现
- 与未加入LSSDR412比较,LSSDR412处理后Hela和Caski细胞的存活率、克隆数、侵袭和迁移细胞数均显著降低(P均<0.05),且呈浓度依赖趋势。
- LSSDR412组小鼠瘤体重量显著低于对照组[(0.292±0.073) vs (0.480±0.117)g;t=3.341,P=0.008]。
- LSSDR412组肿瘤组织Ki-67阳性率显著低于对照组(21.95%±5.60% vs 87.27%±6.35%;t=26.72,P<0.001)。
- LSSDR412组肺内转移灶占比显著低于对照组[25.0%(16.3%,45.0%) vs 39.1%(31.3%,48.3%);U=31.00,P=0.044]。
- LSSDR412组小鼠肝、肾组织结构无明显病理性改变。
关键数值与推荐
- LSSDR412处理后Hela和Caski细胞存活率、克隆数、侵袭和迁移细胞数均显著降低(P均<0.05)。
- LSSDR412组瘤体重量(0.292±0.073)g低于对照组(0.480±0.117)g(t=3.341,P=0.008)。
- LSSDR412组Ki-67阳性率21.95%±5.60%低于对照组87.27%±6.35%(t=26.72,P<0.001)。
- LSSDR412组肺内转移灶占比25.0%(16.3%,45.0%)低于对照组39.1%(31.3%,48.3%)(U=31.00,P=0.044)。
临床怎么用
- 该研究为LSSDR412的临床转化提供理论基础,提示其可能通过抑制CLDN4/Wnt/β-catenin通路发挥抗宫颈癌作用。
- 目前证据限于体外细胞和裸鼠模型,尚不能直接用于临床决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To investigate the effects and underlying mechanisms of the recombinant bee venom peptide LSSDR412 on the malignant biological behavior of cervical cancer in vitro and in vivo, and to provide a theoretical basis for its potential clinical translation. Methods: Peptide LSSDR412 was obtained by chemical synthesis. Different concentrations of LSSDR412 were used as treatment groups. The effects of peptide LSSDR412 on the survival and proliferation of cervical cancer cell lines (Hela cells and Caski cells) were detected by cell counting kit-8 (CCK-8) and clone formation assay. Transwell chamber assay was used to detect the effect on cell migration and invasion. Western blot and co-immunoprecipitation assay were used to detect the expression and interaction of epithelial-mesenchymal transition (EMT) and Wnt/β-catenin signaling pathway related proteins. The cervical cancer xenograft model was established in nude mice, and the volume of subcutaneous xenograft tumor was detected after intraperitoneal injection of LSSDR412. The expression of the proliferation associated nuclear antigen (Ki-67) was detected by immunofluorescence. The lung metastasis model of cervical cancer bearing nude mice was established, and HE staining was used to detect the effect of intraperitoneal injection of LSSDR412 on lung metastasis. Results: Compared with the cells without LSSDR412 treatment, the survival rate, clone number, invasive and migratory cell number of Hela and Caski cells were significantly decreased after LSSDR412 treatment (all P<0.05), and showed a concentration-dependent trend. LSSDR412 could inhibit the EMT process of cervical cancer and inhibit the Wnt/β-catenin signaling pathway through Claudin-4 (CLDN4) to play an anti-cervical cancer effect. The results of in vivo experiments showed that the tumor weight of the LSSDR412 group was significantly lower than that of the control group [(0.292±0.073) vs (0.480±0.117) g; t=3.341, P=0.008]. The positive rate of Ki-67 in tumor tissue was significantly lower than that in the control group (21.95%±5.60% vs 87.27%±6.35%; t=26.72, P<0.001), and the proportion of intrapulmonary metastases was significantly lower than that of the control group [25.0% (16.3%, 45.0%) vs 39.1% (31.3%, 48.3%); U=31.00, P=0.044]. There was no significant pathological change in liver and kidney tissue structure in the LSSDR412 group. Conclusions: Peptide LSSDR412 shows significant inhibitory effects on the proliferation, migration and invasion of cervical cancer cells both in vitro and in vivo with no apparent toxic side effects. Its antitumor activity is primarily mediated through the suppression of the CLDN4-mediated Wnt/β-catenin signaling pathway. 目的: 探讨重组蜂毒多肽LSSDR412对子宫颈癌恶性生物学行为的影响及作用机制,为LSSDR412的临床转化研究提供理论基础。 方法: 通过化学合成方法获得多肽LSSDR412。实验组为不同浓度的多肽LSSDR412,通过活细胞计数(CCK-8)和平板克隆实验检测其对子宫颈癌细胞系(Hela细胞和Caski细胞)存活和增殖能力的影响;穿膜小室实验检测其对细胞迁移和侵袭能力的影响;蛋白印迹(western blot)和免疫共沉淀实验检测其对上皮间质转化(EMT)、Wnt/β-连环蛋白(β-catenin)信号通路相关蛋白表达及相互作用关系的影响;构建子宫颈癌荷瘤裸鼠皮下移植瘤模型,检测LSSDR412腹腔注射给药后皮下移植瘤体积的变化,免疫荧光法检测细胞增殖相关核抗原(Ki-67)的表达情况;构建子宫颈癌荷瘤裸鼠肺转移模型,HE染色检测LSSDR412腹腔注射给药后对肺部转移瘤的影响。 结果: 与未加入LSSDR412比较,LSSDR412处理后Hela和Caski细胞的存活率、克隆数、侵袭和迁移细胞数均显著降低(P均<0.05),且呈浓度依赖趋势。LSSDR412对子宫颈癌的EMT过程起抑制作用,且可通过封闭蛋白4(CLDN4)介导的Wnt/β-catenin信号通路的抑制,发挥抗子宫颈癌作用。体内实验结果显示,LSSDR412组小鼠的瘤体重量显著低于对照组[分别为(0.292±0.073)、(0.480±0.117)g;t=3.341,P=0.008],肿瘤组织Ki-67阳性率显著低于对照组(分别为21.95%±5.60%、87.27%±6.35%;t=26.72,P<0.001),肺内转移灶占比显著低于对照组[分别为25.0%(16.3%,45.0%)、39.1%(31.3%,48.3%);U=31.00,P=0.044]。LSSDR412组小鼠的肝、肾组织结构无明显病理性改变。 结论: 多肽LSSDR412对子宫颈癌细胞的增殖、迁移和侵袭均显示出显著的抑制作用且无明显的药物毒副作用,主要通过抑制CLDN4介导的Wnt/β-catenin信号通路发挥作用。.
引用
- Wu SY, Wang DY, He JX, et al. [Experimental study on the inhibitory effects of recombinant bee venom peptide on the malignant biological behavior of cervical cancer]. Zhonghua Fu Chan Ke Za Zhi. 2026. PMID: 42045782. doi:10.3760/cma.j.cn112141-20251117-00551
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。